Mohab M. Ibrahim

Mohab M. Ibrahim

Auto-generated profile, based on publicly available information

Mohab M. Ibrahim

Comprehensive Center for Pain and Addiction at the University of Arizona Health Sciences. Tucson, AZ, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in The Journal of Pain
Verified
Journal Article
Closed access
KCKevin Cheng
Kevin Cheng
LMLaurent F. Martin
Laurent F. Martin
MSMarvin J. Slepian
Marvin J. Slepian
APAmol M. Patwardhan
Amol M. Patwardhan
MIMohab M. Ibrahim
Mohab M. Ibrahim

19 November 2016 in Pain
Verified
Journal Article
Closed access
MIMohab M. Ibrahim
Mohab M. Ibrahim
APAmol Patwardhan
Amol Patwardhan
KGKerry B. Gilbraith
Kerry B. Gilbraith
AMAubin Moutal
Aubin Moutal
XYXiaofang Yang
Xiaofang Yang
Rajesh KhannaRajesh Khanna
Rajesh Khanna
Treatments for chronic pain are inadequate, and new options are needed. Nonpharmaceutical approaches are especially attractive with many potential advantages including safety. Light therapy has been suggested to be beneficial in certain medical conditions such as depression, but this approach remains to be explored for modulation of pain. We investigated the effects of light-emitting diodes (LEDs), in the visible spectrum, on acute sensory thresholds in naive rats as well as in experimental neuropathic pain. Rats receiving green LED light (wavelength 525 nm, 8 h/d) showed significantly increased paw withdrawal latency to a noxious thermal stimulus; this antinociceptive effect persisted for 4 days after termination of last exposure without development of tolerance. No apparent side effects were noted and motor performance was not impaired. Despite LED exposure, opaque contact lenses prevented antinociception. Rats fitted with green contact lenses exposed to room light exhibited antinociception arguing for a role of the visual system. Antinociception was not due to stress/anxiety but likely due to increased enkephalins expression in the spinal cord. Naloxone reversed the antinociception, suggesting involvement of central opioid circuits. Rostral ventromedial medulla inactivation prevented expression of light-induced antinociception suggesting engagement of descending inhibition. Green LED exposure also reversed thermal and mechanical hyperalgesia in rats with spinal nerve ligation. Pharmacological and proteomic profiling of dorsal root ganglion neurons from green LED-exposed rats identified changes in calcium channel activity, including a decrease in the N-type (CaV2.2) channel, a primary analgesic target. Thus, green LED therapy may represent a novel, nonpharmacological approach for managing pain.

9 September 2020 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
LMLaurent F Martin
Laurent F Martin
APAmol M Patwardhan
Amol M Patwardhan
SJSejal V Jain
Sejal V Jain
MSMichelle M Salloum
Michelle M Salloum
JFJulia Freeman
Julia Freeman
MIMohab M Ibrahim
Mohab M Ibrahim
Background: Pharmacological management of migraine can be ineffective for some patients. We previously demonstrated that exposure to green light resulted in antinociception and reversal of thermal and mechanical hypersensitivity in rodent pain models. Given the safety of green light emitting diodes, we evaluated green light as a potential therapy in patients with episodic or chronic migraine. Material and methods: We recruited (29 total) patients, of whom seven had episodic migraine and 22 had chronic migraine. We used a one-way cross-over design consisting of exposure for 1–2 hours daily to white light emitting diodes for 10 weeks, followed by a 2-week washout period followed by exposure for 1–2 hours daily to green light emitting diodes for 10 weeks. Patients were allowed to continue current therapies and to initiate new treatments as directed by their physicians. Outcomes consisted of patient-reported surveys. The primary outcome measure was the number of headache days per month. Secondary outcome measures included patient-reported changes in the intensity and frequency of the headaches over a two-week period and other quality of life measures including ability to fall and stay asleep, and ability to perform work. Changes in pain medications were obtained to assess potential reduction. Results: When seven episodic migraine and 22 chronic migraine patients were analyzed as separate cohorts, white light emitting diodes produced no significant change in headache days in either episodic migraine or chronic migraine patients. Combining data from the episodic migraine and chronic migraine groups showed that white light emitting diodes produced a small, but statistically significant reduction in headache days from (days ± SEM) 18.2 ± 1.8 to 16.5 ± 2.01 days. Green light emitting diodes resulted in a significant decrease in headache days from 7.9 ± 1.6 to 2.4 ± 1.1 and from 22.3 ± 1.2 to 9.4 ± 1.6 in episodic migraine and chronic migraine patients, respectively. While some improvement in secondary outcomes was observed with white light emitting diodes, more secondary outcomes with significantly greater magnitude including assessments of quality of life, Short-Form McGill Pain Questionnaire, Headache Impact Test-6, and Five-level version of the EuroQol five-dimensional survey without reported side effects were observed with green light emitting diodes. Conclusions regarding pain medications reduction with green light emitting diode exposure were not possible. No side effects of light therapy were reported. None of the patients in the study reported initiation of new therapies. Discussion: Green light emitting diodes significantly reduced the number of headache days in people with episodic migraine or chronic migraine. Additionally, green light emitting diodes significantly improved multiple secondary outcome measures including quality of life and intensity and duration of the headache attacks. As no adverse events were reported, green light emitting diodes may provide a treatment option for those patients who prefer non-pharmacological therapies or may be considered in complementing other treatment strategies. Limitations of this study are the small number of patients evaluated. The positive data obtained support implementation of larger clinical trials to determine possible effects of green light emitting diode therapy. This study is registered with clinicaltrials.gov under NCT03677206.

4 February 2021 in Pain Medicine
Verified
Journal Article
Open access
PDF file
LMLaurent Martin
Laurent Martin
FPFrank Porreca
Frank Porreca
EMElizabeth I Mata
Elizabeth I Mata
MSMichelle Salloum
Michelle Salloum
VGVasudha Goel
Vasudha Goel
MIMohab M Ibrahim
Mohab M Ibrahim
Objective: Fibromyalgia is a functional pain disorder in which patients suffer from widespread pain and poor quality of life. Fibromyalgia pain and its impact on quality of life are not effectively managed with current therapeutics. Previously, in a preclinical rat study, we demonstrated that exposure to green light-emitting diodes (GLED) for 8 hours/day for 5 days resulted in antinociception and reversal of thermal and mechanical hypersensitivity associated with models of injury-related pain. Given the safety of GLED and the ease of its use, our objective is to administer GLED as a potential therapy to patients with fibromyalgia. Design: One-way crossover clinical trial. Setting: United States. Method: We enrolled 21 adult patients with fibromyalgia recruited from the University of Arizona chronic pain clinic who were initially exposed to white light-emitting diodes and then were crossed over to GLED for 1 to 2 hours daily for 10 weeks. Data were collected by using paper surveys. Results: When patients were exposed to GLED, but not white light-emitting diodes, they reported a significant reduction in average pain intensity on the 10-point numeric pain scale. Secondary outcomes were assessed by using the EQ-5D-5L survey, Short-Form McGill Pain Questionnaire, and Fibromyalgia Impact Questionnaire and were also significantly improved in patients exposed to GLED. GLED therapy was not associated with any measured side effects in these patients. Conclusion: Although the mechanism by which GLED elicits pain reduction is currently being studied, these results supporting its efficacy and safety merit a larger clinical trial.

23 October 2022 in The Journal of Pain
Verified
Journal Article
Closed access
LMLaurent F. Martin
Laurent F. Martin
KCKevin Cheng
Kevin Cheng
SWStephanie M. Washington
Stephanie M. Washington
MDMillie Denton
Millie Denton
VGVasudha Goel
Vasudha Goel
MIMohab M. Ibrahim
Mohab M. Ibrahim

19 June 2021 in The Journal of Pain
Verified
Journal Article
Closed access
LMLaurent F. Martin
Laurent F. Martin
AMAubin Moutal
Aubin Moutal
KCKevin Cheng
Kevin Cheng
SWStephanie M. Washington
Stephanie M. Washington
HCHugo Calligaro
Hugo Calligaro
MIMohab M. Ibrahim
Mohab M. Ibrahim